Compare UiPath Inc (PATH) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs 10X Genomics Inc — how do they compare? UiPath Inc trades at $13.58 (market cap $7.26B), while 10X Genomics Inc trades at $67.8 (market cap $8.55B). The key difference: 10X Genomics Inc is the larger of the two by market cap, and 10X Genomics Inc is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals.
| PATH | TXG | |
|---|---|---|
Market Cap | $7.26B | $8.55B |
Sector | Technology | Health |
52-Week High | $19.29 | $67.29 |
52-Week Low | $9.38 | $11.34 |
Enterprise Value | $6.05B | $8.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $14.01, down 7.77% amid mixed signals. The stock is near its consensus price target low of $14.00. Revenue growth is improving, with 2025 revenue at $1.43 billion and a projected net profit margin of 21.03% for 2026. Technical indicators show a bearish near-term trend with RSI at oversold levels, while recent news highlights volatility following Q2 earnings.
The outlook is cautious; PATH shows fundamental improvement but faces execution risks and competitive pressure. Analyst consensus is predominantly Hold (70.84%), with a $17.38 price target suggesting modest upside. Key risks include slowing growth guidance and macroeconomic headwinds impacting software demand.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
